Company
Arcus Biosciences
Arcus Biosciences has 13 drugs tracked on RxWires: 3 in Phase 3, 3 in Phase 2, 2 in Phase 1/2, 5 in Phase 1.
Pipeline
| Drug | Phase | Indication |
|---|---|---|
| Quemliclustat | Phase 3 | Metastatic Pancreatic Ductal Adenocarcinoma |
| Casdatifan | Phase 3 | Metastatic Clear Cell Renal Cell Carcinoma |
| Domvanalimab | Phase 3 | Advanced Upper Gastrointestinal Tract Adenocarcinoma |
| Zimberelimab | Phase 2 | Non Small Cell Lung Cancer |
| Atezolizumab | Phase 2 | Prostate Adenocarcinoma |
| Etrumadenant (AB928) | Phase 2 | Rectal Cancer |
| AB680 | Phase 1/2 | Metastatic Colorectal Cancer |
| Biospecimen Collection | Phase 1/2 | Borderline Resectable Pancreatic Adenocarcinoma |
| AB801 | Phase 1 | Advanced Cancer |
| AB598 | Phase 1 | Advanced Cancer |
| AB308 | Phase 1 | Advanced Solid Tumor |
| [14C]-etrumadenant | Phase 1 | Healthy Participants |
| AB102 | Phase 1 |
Latest
- Domvanalimab moved to Phase 3
- Casdatifan moved to Phase 3
- arcus biosciences filed 8-K
- arcus biosciences filed 8-K
- arcus biosciences filed 8-K
Follow Arcus Biosciences on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.